Journal
CANCER BIOLOGY & MEDICINE
Volume 15, Issue 3, Pages 189-209Publisher
CHINESE ANTI-CANCER ASSOC
DOI: 10.20892/j.issn.2095-3941.2018.0037
Keywords
CAR-T cells; immune checkpoint blockade; bispecific antibodies
Categories
Funding
- NIH [R01 CA136934, R01 CA193167]
Ask authors/readers for more resources
The development of immunotherapies for lymphoma has undergone a revolutionary evolution over the past decades. Since the advent of rituximab as the first successful immunotherapy for B-cell non-Hodgkin lymphoma over two decades ago, a plethora of new immunotherapeutic approaches to treat lymphoma has ensued. Four of the most exciting classes of immunotherapies include: chimeric antigen receptor T-cells, bispecific antibodies, immune checkpoint inhibitors, and vaccines. However, with addition of these novel therapies the appropriate timing of treatment, optimal patient population, duration of therapy, toxicity, and cost must be considered. In this review, we describe the most-promising immunotherapeutic approaches for the treatment of lymphoma in clinical development, specifically focusing on clinical trials performed to date and strategies for improvement.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available